Richard Plemper, a world-renowned virologist who has already made great strides in drug development and pandemic preparedness, will work with his team to continue to enhance collaborative research to prevent future pandemics from occurring. This transformative work will focus on detecting and even preventing the next pandemic. By creating a network of dozens of centers across the U.S., Richard Plemper and his team of researchers will leverage the university’s excellence in antiviral drug development with cutting-edge expertise in diagnostics engineering and bioinformatics modeling.
Working together to Enhance Preparedness against Pandemics. (WE-prep) is based on the premise that a pharmacological first-line defense of broad-spectrum drugs can mitigate the major clinical burden caused by emerging and reemerging RNA viruses and improve preparedness against future pandemics. The work will focus on the immediate task of drug development while growing the knowledge base about early detection drug administration strategies and the role of antivirals on late-stage disease complications such as Long COVID-19.
Plemper’s research during the pandemic has led to the new anti-viral drug Remdesivir, the only antiviral drug approved by the FDA for the treatment of COVID-19.
2022 Project RISE Award: $300,000